Research programme: cardiovascular disorder therapeutics - Qurgen
Latest Information Update: 06 Sep 2023
At a glance
- Originator Qurgen
- Class Cardiovascular therapies; Heart failure therapies; Proteins
- Mechanism of Action Cell differentiation modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Heart failure; Myocardial infarction
Most Recent Events
- 27 Aug 2023 Qurgen has patent protection and patents pending, regarding "Methods, systems and compositions relating to cell conversion via protein induced in-vivo cell reprogramming" in various countries
- 24 Aug 2023 Preclinical trials in Heart failure in China (Parenteral) (Qurgen pipeline, August 2023)
- 24 Aug 2023 Preclinical trials in Heart failure in USA (Parenteral) (Qurgen pipeline, August 2023)